Skip to content

The Aesthetic Surgery Education and Research Foundation

Newsroom
Now Accepting Applications for 2022 ASERF Resident Travel Scholarship Print

Are you a resident or fellow looking for funding to attend The Aesthetic Meeting 2022 in San Diego, California? Consider applying for the ASERF Resident Travel Scholarship. We are now accepting applications through December 1, 2021.

» Apply Now!

Purpose: ASERF established the Resident Travel Scholarship to benefit residents and fellows by providing financial support for travel expenses associated with attending The Aesthetic Meeting. We will be awarding 25 grants, in the amount of $2,000 each to the residents and fellows selected.

Uses:  Scholarship funds must be used to offset the costs of travel, hotel, and other expenses associated with attending The Aesthetic Meeting 2022.

Qualifying Criteria

ASERF Resident Travel Scholarship applicants must meet the following criteria:

  • Must be enrolled and in good standing in an approved plastic surgery training program in the U.S./Canada
  • Submit a letter of recommendation from the resident or fellow’s program director
  • Submit a Curriculum Vitae (CV)
  • Submit an essay explaining the importance of attending The Aesthetic Meeting 2022  
  • Agree to attend the entire educational session during the meeting
  • Agree to accept the scholarship funding after the annual meeting for which the scholarship was provided (to ensure attendance)
  • Agree to write a short article about their most important learning experience during the meeting, which may be used in an issue of Aesthetic Society News


» Apply Now!

 
Tranexamic Acid Pharmacokinetics in Tumescent Solution: What Dose is Safe? Print

Researcher: Joseph Hunstad, MD

Grant Award: ASERF Interim Grant

Amount Awarded: $18,095

Project Name: Tranexamic Acid Pharmacokinetics in Tumescent Solution: What Dose is Safe?

Project Summary: The overall aim of this study is to evaluate the efficacy of tranexamic acid (TXA) administered subcutaneously within tumescent fluid on blood loss, ecchymosis and seroma rates using a prospective, blinded, randomized control trial. Additionally, we will evaluate the pharmacokinetics of TXA using mass microscopy. The results of this study will provide preliminary definitive information on the efficacy of TXA reducing blood loss for liposuction procedures for plastic surgeons, and the safety profile of TXA when added to tumescent solution. These data, and knowledge obtained from our study, will contribute to advances in aesthetic plastic surgery, especially reduction in blood loss. The goal is to guide plastic surgeons in applying evidence-based medicine to their practices to prevent complications and improve outcomes.

The primary objective is to determine the efficacy of TXA in preventing postoperative ecchymosis, seroma, and intraoperative blood loss as well as the pharmacokinetics of TXA. We will investigate the amount of blood loss in liposuction infranatant fluid after infiltration with tumescent solution containing TXA compared to tumescent fluid without TXA. Lastly, we will objectively and subjectively assess postoperative bruising using artificial intelligence.

We hypothesize that the use of tumescent infiltration containing TXA into the subcutaneous tissue will reduce blood loss, bruising and seroma rates. We also hypothesize that a dose of 500 mg of TXA (1 cc/mL) added to 1L of tumescent solution will be a safe dose of TXA without added risk of toxicity.

Upon completion of the study, it is our expectation that we will be able to demonstrate the safety of TXA added to tumescent solution by its pharmacokinetic profile. We expect to show a significant decrease in intraoperative blood loss, postoperative ecchymosis, and seroma rates in the TXA study group compared to the standard tumescent liposuction control group.

 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 3 of 39


Copyright © 2009-2018 ASERF. 11262 Monarch St., Garden Grove, CA 92841-1441 P: 800-364-2147 F: 562-799-1098